Quick Summary
- Orforglipron 36 mg reduced A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in the ACHIEVE-3 trial. 85.4% of orforglipron patients achieved A1C <7% target vs. 66.1% on semaglutide, establishing superior glycemic control.
- Orforglipron is a once-daily small-molecule GLP-1 that requires no food or water timing restrictions, unlike some alternatives, improving medication adherence and patient convenience.
- Beyond glucose/weight improvements, orforglipron showed clinically meaningful reductions in non-HDL cholesterol, triglycerides, and systolic blood pressure—addressing broader cardiometabolic risk factors.
- Eli Lilly has submitted orforglipron to 40+ countries with FDA obesity approval expected Q2 2026 and U.S. type 2 diabetes submission planned later in 2026.
Eli Lilly and Company has announced breakthrough results from ACHIEVE-3, a head-to-head clinical trial that establishes orforglipron as a superior oral GLP-1 receptor agonist for type 2 diabetes management. The investigational medication outperformed oral semaglutide across all primary and key secondary endpoints, delivering clinically meaningful improvements in blood sugar control and weight loss. With FDA obesity approval expected in Q2 2026 and regulatory submissions already filed in over 40 countries, orforglipron represents a significant advancement in cardiometabolic treatment options.
Orforglipron Achieves Superior Blood Sugar Control and Weight Loss in ACHIEVE-3 Trial
Primary Efficacy Endpoint: Significant A1C Reduction
In the landmark ACHIEVE-3 trial published in The Lancet, orforglipron demonstrated substantially greater A1C reduction compared to oral semaglutide. The 52-week study enrolled 1,698 participants and evaluated four treatment arms using a randomized design across international sites. Orforglipron 36 mg reduced A1C by 2.2% from a baseline of 8.3%, compared to just 1.4% reduction with the maximum oral semaglutide dose of 14 mg. The lower orforglipron dose of 12 mg also exceeded semaglutide’s performance, reducing A1C by 1.9% versus 1.4%.
The differences in A1C reduction were clinically meaningful,,
These results represent the first head-to-head comparison of oral GLP-1 receptor agonists in type 2 diabetes, establishing orforglipron’s advantage in glycemic control.
Dr. Julio Rosenstock
Secondary Endpoint: Dramatic Weight Loss Advantage
Weight management outcomes revealed even more striking differences between the two medications. Participants receiving orforglipron 36 mg lost an average of 19.7 lbs (8.9 kg, or 9.2% of baseline body weight) over 52 weeks. This compared dramatically to just 11.0 lbs (5.0 kg, or 5.3%) weight loss in the oral semaglutide 14 mg group, representing a 73.6% greater relative weight loss benefit with orforglipron. The 12 mg orforglipron dose also outperformed both semaglutide doses, producing 14.6 lbs (6.6 kg) of weight loss.
Target A1C Achievement Rates
ACHIEVE-3 measured the percentage of participants achieving critical A1C targets associated with reduced diabetes complications. For the stringent goal of A1C below 7%, orforglipron 36 mg achieved an 85.4% response rate compared to 66.1% with oral semaglutide 14 mg. At A1C ≤6.5%, orforglipron 36 mg reached 76.8% of participants versus 50.9% on semaglutide. Even achieving near-normal glycemia (A1C <5.7%) proved superior, with 37.1% of orforglipron 36 mg recipients meeting this target compared to 12.5% on the maximum semaglutide dose.
Read More: Eli Lilly’s Oral Weight-Loss Drug Orforglipron Shows Promising Results in Phase 3 Trial
Clinical Advantages and Patient-Centred Benefits
Flexible Dosing Without Food and Water Restrictions
A distinctive advantage of orforglipron is its formulation flexibility. Unlike some GLP-1 medications requiring specific food and water considerations, orforglipron can be taken any time of day without timing restrictions relative to meals or fluid intake. This practical benefit enhances medication adherence and quality of life for patients managing type 2 diabetes in real-world settings.
Cardiovascular Risk Factor Improvements
Beyond glucose and weight metrics, orforglipron demonstrated clinically meaningful improvements in multiple cardiovascular risk factors, including:
- Non-HDL cholesterol reduction
- HDL cholesterol elevation
- VLDL cholesterol reduction
- Total cholesterol decrease
- Systolic blood pressure lowering
- Triglyceride reduction
These secondary benefits address the broader cardiometabolic complications associated with type 2 diabetes and obesity, aligning with comprehensive cardiovascular risk management strategies.
Safety Profile and Tolerability
Adverse Event Profile
The overall safety and tolerability profile of orforglipron remained consistent with the known safety profile from previous clinical trials. The most commonly reported adverse events included nausea, diarrhea, vomiting, dyspepsia, and decreased appetite, side effects typical of GLP-1 receptor agonist therapy.
Treatment Discontinuation Rates
Treatment discontinuation due to adverse events occurred in 8.7% of participants on orforglipron 12 mg and 9.7% on the 36 mg dose. These rates were higher than oral semaglutide, where discontinuation occurred in 4.5% (7 mg) and 4.9% (14 mg) of participants. Despite the higher discontinuation rate, the superior efficacy outcomes across all primary and secondary endpoints support orforglipron’s clinical value proposition.
Read More: Lilly’s Oral GLP-1 Orforglipron Shows Significant Weight Loss in Phase 3 ATTAIN-1 Trial
ACHIEVE-3 Trial Design and Methodology
Study Population and Protocol
ACHIEVE-3 (NCT06045221) randomized 1,698 adults with inadequately controlled type 2 diabetes despite metformin therapy across sites in the United States, Argentina, China, Japan, Mexico, and Puerto Rico. Participants were randomly assigned to receive either orforglipron or oral semaglutide in a 1:1:1:1 ratio across four arms.
Titration Schedules
Orforglipron participants initiated therapy at 1 mg once daily, titrating upward in four-week intervals to their randomized maintenance dose (12 mg or 36 mg). Oral semaglutide recipients started at 3 mg daily, increasing to their assigned dose (7 mg or 14 mg). The step-wise titration approach minimized gastrointestinal side effects while achieving therapeutic doses.
Efficacy and Treatment-Regimen Estimands
Results were analyzed using two estimation approaches. The efficacy endpoint represented outcomes if all participants maintained study treatment for 52 weeks without initiating additional antihyperglycemic drugs. The treatment-regimen estimand reflected real-world effectiveness regardless of adherence or need for additional medications.
Detailed ACHIEVE-3 Results Summary
Primary Endpoint: A1C Reduction
| Treatment Arm | A1C Change (Efficacy Estimand) | A1C Change (Treatment-Regimen) | Significance |
|---|---|---|---|
| Oral Semaglutide 7 mg | -1.1% | -1.2% | Baseline |
| Oral Semaglutide 14 mg | -1.4% | -1.5% | Standard comparison |
| Orforglipron 12 mg | -1.9% | -1.7% | p<0.01 vs. 14 mg semaglutide |
| Orforglipron 36 mg | -2.2% | -1.9% | p<0.001 vs. both semaglutide doses |
Secondary Endpoint: Weight Loss (from 97.0 kg/213.9 lbs baseline)
| Treatment Arm | Absolute Loss (lbs) | Percentage Loss | Significance |
|---|---|---|---|
| Oral Semaglutide 7 mg | -7.9 | -3.7% | Baseline |
| Oral Semaglutide 14 mg | -11.0 | -5.3% | Standard comparison |
| Orforglipron 12 mg | -14.6 | -6.7% | p<0.001 vs. both semaglutide doses |
| Orforglipron 36 mg | -19.7 | -9.2% | p<0.001 vs. both semaglutide doses |
A1C Achievement Targets at Week 52
| Achievement Target | Semaglutide 7 mg | Semaglutide 14 mg | Orforglipron 12 mg | Orforglipron 36 mg |
|---|---|---|---|---|
| A1C <7% | 54.6% | 66.1% | 80.0% | 85.4% |
| A1C ≤6.5% | 40.9% | 50.9% | 71.8% | 76.8% |
| A1C <5.7% | 7.8% | 12.5% | 25.4% | 37.1% |
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Future Directions and Trial Program
Remaining ACHIEVE Trial Results
Three additional registrational trials within the ACHIEVE program will provide further efficacy and safety data in type 2 diabetes. Results anticipated later in 2026 will broaden the evidence base and potentially support expanded regulatory approvals. These trials likely included different patient populations and diabetes severity profiles.
Obesity Indication Development
Beyond type 2 diabetes, orforglipron’s weight loss efficacy establishes its potential in obesity treatment. FDA obesity indication approval expected in Q2 2026 positions orforglipron to address the growing epidemic of weight-related disease affecting hundreds of millions globally.
Cardiometabolic and Sleep Medicine Applications
Research into orforglipron for obstructive sleep apnea and hypertension in obesity recognizes that these conditions share common pathophysiological mechanisms with metabolic dysfunction. GLP-1 receptor activation may provide therapeutic benefits beyond glucose and weight management through cardiovascular, respiratory, and metabolic pathways.
Last Modified:
